Jacqueline Barrientos, MD, MS, Feinstein Institute for Medical Research, Manhasset, NY, outlines the challenges associated with choosing the most appropriate therapeutic regimen for the treatment of chronic lymphocytic leukemia (CLL) in a rapidly evolving field. In particular, Dr Barrientos discusses the advantages and disadvantages of BTK inhibitor therapies, such as ibrutinib and acalabrutininb, compared to fixed-duration BCL-2 inhibitor therapy in combination with obinutuzumab. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.